Vortioxetine Synthesis via Copper Catalysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing vortioxetine are inefficient, with low yields and high costs due to the use of expensive palladium-based catalysts and complex phosphine ligands, necessitating a more economical and efficient process.
Innovation Solution
A process involving the formation of the piperazine ring using a compound of formula (IV) with aldehyde or carboxy groups, reacting with a compound of formula (V) in the presence of a reducing agent and solvent, and optionally using palladium or platinum catalysts under hydrogen transfer conditions, to produce vortioxetine with higher yields and improved process economy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a palladium-based catalyst and phosphine ligand are used for vortioxetine synthesis, then the reaction yield is improved, but the production cost increases significantly
Solution Approach 1:
The patent replaces expensive palladium catalysts with cheaper copper catalysts that can be used in stoichiometric or near-stoichiometric amounts. The copper catalyst system, while requiring larger quantities, uses inexpensive materials that dramatically reduce overall production costs despite the trade-off in catalyst efficiency and reusability
Solution Approach 2:
The patent changes the catalytic system from palladium-based to copper-based, altering the fundamental parameters of the reaction conditions. This includes adjusting solvents, bases, and temperature parameters to optimize the copper-catalyzed Ullmann coupling reaction, achieving cost-effective synthesis with acceptable yields
2Productivity
If a palladium-based catalyst system is used for vortioxetine synthesis, then the reaction efficiency is improved, but the process complexity increases
Solution Approach 1:
The patent eliminates the need for complex phosphine ligand systems by using simple copper salts as catalysts. This simplification of the catalytic system reduces process complexity while maintaining synthetic efficiency through straightforward copper-mediated coupling reactions
Solution Approach 2:
The patent simplifies the reaction conditions by replacing complex palladium-phosphine systems with copper catalysts that operate under more straightforward conditions. The process uses common solvents and bases, reducing the complexity of equipment and procedural requirements
3Ease of manufacture
If traditional alkylation methods are used to synthesize vortioxetine, then the synthesis simplicity is maintained, but the reaction yield remains low
Solution Approach 1:
The patent extracts the limiting factor from traditional alkylation methods by replacing the alkylation step with a copper-catalyzed Ullmann coupling reaction. This substitution removes the yield limitation inherent in conventional alkylation while preserving the overall simplicity of the synthetic approach
Solution Approach 2:
The patent changes the reaction type from alkylation to Ullmann coupling, fundamentally altering the reaction mechanism and conditions. This parameter change enables higher yields through copper-catalyzed aromatic substitution while maintaining synthetic accessibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves vortioxetine synthesis with chemical purity greater than 99.5% and higher yields, reducing production costs and improving process efficiency.
Implementation Method 1
reacting with a compound of formula (V) in the presence of a reducing agent and solvent, and optionally using palladium or platinum catalysts under hydrogen transfer conditions
Implementation Method 2
optionally using palladium or platinum catalysts under hydrogen transfer conditions
Data Source
AI summary
The present invention relates to a process for the preparation of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine of formula (I), also known as vortioxetine, salts thereof, and intermediates useful for its synthesis.